THE development of a vaccine to provide protective immunity to human immunodeficiency virus type 1 (HIV-1), the virus causing AIDS, would be the most practical method to control its spread. Subunit vaccines consisting of virus envelope glycoproteins, produced by recombinant DNA technology, are effective in preventing viral infections1. We have now used this approach in the development of a candidate AIDS vaccine. Chimpanzees were immunized with recombinant forms of the HIV-1 glycoproteins gp120 and gp160 produced in Chinese hamster ovary cells, and then challenged with HIV-1. The control and the two animals immunized with the gp160 variant became infected within 7 weeks of challenge. The two animals immunized with the gp120 variant have shown no signs of infection after more than 6 months. These studies demonstrate that recombinant gp120, formulated in an adjuvant approved for human use, can elicit protective immunity against a homologous strain of HIV-1.
Subscribe to Journal
Get full journal access for 1 year
only $3.90 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Scolnick, E. M. et al. J. Am. med. Assoc. 251, 2812–2815 (1984).
Lasky, L. A. et al. Science 233, 209–21 (1986).
Berman, P. W. et al. J. Virol. 63, 3489–3498 (1989).
Lasky, L. A. et al. Cell 50, 975–985 (1987).
Leonard, C. K. et al. J. biol. Chem. (in the press).
Berman, P. W., Gregory, T., Crase, D. & Lasky, L. A. Science 277, 1490–1492 (1985).
Berman, P. W. et al. Proc. natn. Acad. Sci. U.S.A. 85, 5200–5204 (1988).
Anderson, K. P. et al. J. infect. Diseases 160, 960–969 (1989).
Robertson, G. A., Kostek, B. M., Schleif, W. A., Lewis, J. A. & Emini, E. A. J. virol. Meth. 20, 195–202 (1988).
Arthur, L. O. J. Virol. 63, 5046–5053 (1989).
Prince, A. M. et al. Proc. natn. Acad. Sci. U.S.A. 85, 6944–6948 (1988).
Emini, E. A. et al. J. Virol. (in the press).
Kellog, D. E. & Kwok, S. in PCR Protocols (ed. Innis, M. A., Gelfand, D. H., Sninsky, J. J. & White, J.) 337–347 (Academic, New York, 1990).
Rusche, J. R. et al. Proc. natn. Acad. Sci. U.S.A. 85, 3198–3202 (1988).
Massey, R. J. & Schochetman, G. Science 213, 447–449 (1981).
Homsy, J., Meyer, Mia, Tateno, M., Clarkson, S. & Levy, J. A. Science 244, 1357–1359 (1989).
Robinson, E. W. Jr, Montefiori, D. C. & Mitchell, W. M. Lancet i, 790–794 (1988).
Robinson, E. W. Jr et al. Proc. natn. Acad. Sci. U.S.A. 87, 3185–3189 (1990).
Germain, R. N. Nature 322, 687–689 (1986).
About this article
Cite this article
Berman, P., Gregory, T., Riddle, L. et al. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 345, 622–625 (1990). https://doi.org/10.1038/345622a0
Frontiers in Immunology (2020)
Clinical Therapeutics (2020)
A recombinant gp145 Env glycoprotein from HIV-1 expressed in two different cell lines: Effects on glycosylation and antigenicity
PLOS ONE (2020)
Therapeutic Advances in Vaccines and Immunotherapy (2020)
Identification and CRISPR/Cas9 Inactivation of the C1s Protease Responsible for Proteolysis of Recombinant Proteins Produced in CHO Cells
Biotechnology and Bioengineering (2019)